Bial signs agreement with biotechnology company dedicated to rare diseases

The purpose of the partnerships is to resume the development of promising therapies that were in the clinical trial phase but that were discontinued due to financial and market challenges.

Research work will be initiated in up to three projects. The next investigations will be funded with part of the revenues obtained.

Portuguese pharmaceutical company BIAL has agreed to be a founding member of the biotechnology company ‘Orphan Therapeutics Accelerator’ (OTXL), focused on sourcing and restarting the development of promising ‘shelved’ clinical-stage drugs for ultra-rare diseases and providing a pathway to commercialization. The agreement with the biotechnology company will speed up research into rare diseases and, as a founding member, Bial will play a fundame…